GU Cancers 2025 | The future of molecular profiling in bladder cancer

Alan Tan • 14 Feb 2025

GU Cancers 2025

Alan Tan, MD, Vanderbilt Ingram Cancer Center, Nashville, TN, discusses the growing role of molecular profiling in bladder cancer diagnosis and treatment selection. With biomarkers like fibroblast growth factor receptor 3 (FGFR3) and human epidermal growth factor receptor 2 (HER2) becoming increasingly relevant, next-generation sequencing (NGS) and urinary tumor DNA (utDNA) testing may help identify more patients eligible for targeted therapies. As accessibility improves, molecular profiling could become a standard tool to guide personalized treatment strategies. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.